Skip to content

Change in Prepaids at other companies

Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
-$950K+84.3%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
-$4.31M-128%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidExpense.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's change in prepaids.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's change in prepaids?
MoonLake Immunotherapeutics (MLTX) reported change in prepaids of $10.1M in Q1 2026.
How has MoonLake Immunotherapeutics's change in prepaids changed year-over-year?
MoonLake Immunotherapeutics's change in prepaids increased by 3799.6% year-over-year, from -$273K to $10.1M.
What is the long-term trend for MoonLake Immunotherapeutics's change in prepaids?
Over 2 years (2021 to 2025), MoonLake Immunotherapeutics's change in prepaids has grown at a 89.5% compound annual growth rate (CAGR), from -$156.14K to -$561K.
What does change in prepaids mean?
This metric tracks the net change in cash outflows for goods or services that have been paid for in advance but not yet consumed or recognized as expenses. An increase typically indicates higher future operational commitments, while a decrease suggests the consumption of previously paid assets. It is a key indicator of short-term working capital management and cash flow timing.